The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Glioblastoma Multiforme (GBM) Treatment Market Over The 2026–2030 Period?
The market for glioblastoma multiforme (gbm) treatment has expanded rapidly in recent years. It is forecast to grow from $2.73 billion in 2025 to $3.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. The growth observed in the past can be attributed to factors such as limited survival outcomes, a reliance on surgery and radiation, the standardization of chemotherapy, the increasing number of neuro-oncology centers, and a rise in brain tumor diagnoses.
The glioblastoma multiforme (gbm) treatment market size is projected to experience rapid expansion in the coming years. It is expected to grow to $4.46 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.2%. The growth during the forecast period can be attributed to advancements in targeted therapies, the expansion of immunotherapy pipelines, increased adoption of precision medicine, heightened clinical trial activity, and rising research funding. Major trends anticipated in this period include the increasing adoption of multimodal treatment regimens, greater utilization of tumor treating field therapy, a growing focus on personalized gbm therapies, the broadening of immunotherapy approaches, and improved post-surgical treatment protocols.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Glioblastoma Multiforme (GBM) Treatment Market Expansion?
The increasing occurrence of brain disorders is projected to fuel the expansion of the glioblastoma multiforme (GBM) treatment market. Brain disorders are conditions involving atypical functioning of the brain, as well as the nerves dispersed across the human body and the spinal cord. The rising frequency of brain disorders, including glioblastoma multiforme (GBM), stems from various factors such as an aging population, compromised immune systems, overdiagnosis, exposure to ionizing radiation, and air pollution, thereby creating a demand for their treatment to improve quality of life. As an illustration, in February 2025, Dementia Australia, an Australia-based non-profit organization, stated that around 433,300 Australians are living with dementia, a number predicted to climb to 812,500 by 2054. Additionally, younger-onset dementia impacts approximately 29,000 people in 2025, with this figure anticipated to rise to 41,000 by 2054. Thus, the growing prevalence of brain disorders is significantly boosting the glioblastoma multiforme (GBM) treatment market.
How Is The Glioblastoma Multiforme (GBM) Treatment Market Organized By Segment Classification?
The glioblastoma multiforme (gbm) treatment market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, R Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies
What Emerging Trends Are Seen In The Glioblastoma Multiforme (GBM) Treatment Market?
Leading firms in the industry are concentrating on creating advanced wearable and portable technologies to maintain their competitive edge. Such innovations seek to provide users with improved functionality, greater convenience, and increased comfort, thereby meeting the rising need for readily available and effective healthcare options. An example is Novocure, an oncology company based in Jersey, which introduced Optune Gio in 2023, an FDA-approved wearable and portable treatment system for individuals recently diagnosed with glioblastoma (GBM). The device utilizes Tumor Treating Fields (TTFields), consisting of alternating electric fields designed to interfere with cancer cell division, potentially prolonging patient life. With a weight of only 2.7 pounds, Optune Gio is engineered for comfort, enabling patients to use it during their everyday routines.
Who Are The Industry Participants Involved In The Glioblastoma Multiforme (GBM) Treatment Market?
Major companies operating in the glioblastoma multiforme (gbm) treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, Loxo Oncology Inc., Karyopharm Therapeutics Inc., EnGeneIC Ltd., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc
Get The Full Glioblastoma Multiforme (GBM) Treatment Market Report:
Which Region Leads The Glioblastoma Multiforme (GBM) Treatment Market In Overall Market Size?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Glioblastoma Multiforme (GBM) Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Glioblastoma Multiforme (GBM) Treatment Market 2026, By The Business Research Company
Adult Malignant Glioma Therapeutics Market Report 2026
Glioblastoma Multiforme Market Report 2026
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report
Glioma Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model